PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC Sep 1, 2012.
Published in final edited form as:
PMCID: PMC3162556
NIHMSID: NIHMS317525
Beyond Phosphorylation: Nuclear Export in Vascular Remodeling
Jane EB Reusch, MD
Jane EB Reusch, Section of Endocrinology, Veterans Affairs Medical Center, Denver, Colorado 80220 Department of Medicine, University of Colorado Denver, Aurora, Colorado 80045;
Corresponding Author: Jane EB Reusch MD, Section of Endocrinology (111H), Veterans Affairs Medical Center, 1055 Clermont Street, Denver, CO 80220, Phone: 303 399-8020 ext. 2775, Fax: 303 393-5271, jane.reusch/at/ucdenver.edu
The vasculature is comprised of endothelial cells, vascular smooth muscle cells (VSMCs), fibroblasts and immune cells with closely integrated functions. It is exposed to a variable environment of pulsatile flow and changing blood pressure, plus fluctuations in nutrient, oxidative and cytokine stress. Adaptation to this changing environment is critical for sustained vascular health. VSMC undergo a phenotype change in response to vascular injury including migration, proliferation and matrix production also known as VSMC activation or phenotypic modulation. VSMC activation contributes to the progression of atherosclerosis and post-angioplasty restenosis. Understanding the endogenous regulators of vascular plasticity and adaptation has revealed potential targets for pharmacological intervention to prevent vascular stenosis. For example, Ross and colleagues established cyclic AMP as a critical signaling pathway for the maintenance of VSMC quiescence1. Since that time, agents which increase cAMP, such as phosphodiesterase inhibitors, have demonstrated usefulness as vasodilators with clinical implications for pulmonary hypertension 2, 3. Intracellular accumulation of cAMP signals to protein kinase A and cAMP-responsive Rap1 guanine nucleotide exchange factor, Epac; simultaneous activation of both of these pathways by cAMP is essential for the anti-proliferative impact on VSMCs 3, 4.
The article by Chen et. al. in this issue demonstrates that the phosphodiesterase inhibitor cilostazol increases VSMC differentiation via cAMP signaling to the transcription factor CREB, cAMP Response Element Binding Protein(). This result is consistent with reports that active CREB prevents mitogen stimulated migration and proliferation in VSMCs and that dominant negative CREB or CREB silencing have the converse effect 5, 6. Contradictions to the VSMC differentiating effect of CREB were suggested by an earlier report that balloon angioplasty increases CREB phosphorylation transiently and adenoviral delivery of dominant negative CREB (DN CREB) at the time of balloon angioplasty decreases neointimal plaque formation 7. Consistent with Tokunou et al, Chen et al. demonstrate that balloon injury leads to CREB phosphorylation. Chen’s data offer some new insights into how to interpret these apparently conflicting data. Chen et. al. demonstrate that cilostazol leads to CREB phosphorylation and nuclear localization, whereas balloon injury leads to CREB phosphorylation with exclusion from the nucleus(). In vivo proliferation with CREB nuclear export is consistent with our original report demonstrating loss of pulmonary artery CREB overlapping with increased in proliferation detected by Ki67 in the hypoxic neonatal calf model 6. We have previously reported nuclear exclusion of phosphorylated CREB in response to platelet derived growth factor (PDGF), oxidized LDL and cytokine mixtures 5, 8, 9. Cellular localization, nuclear environment (Redox state, activity of other transcription factors and co-repressor or co-activator proteins) and DNA context (acetylation, methylation) all contribute to the nuclear interpretation of CREB phosphorylation 10. Acute nuclear exclusion of CREB in response to balloon injury would be expected to acutely decrease the cAMP dependent CREB gene expression that maintains VSMC differentiation. It remains enigmatic that adenoviral DN CREB also decreased neointimal formation suggesting a difference between the CREB regulation by cilostazol and the transcriptional response to the DN CREB adenovirus.
VSMC plasticity is critical for vascular health and acutely regulated by nuclear localization of transcription factors and cofactors. In response to injury, changes in VSMC proliferation, migration and matrix production are essential for adaptive remodeling such as wound healing. In restenosis or the neointimal phase of atherosclerosis progression, this remodeling response is exaggerated. Nuclear export of CREB is a robust response to VSMC mitogen or oxidant challenge and now balloon injury5, 9(). Reports indicate that neuronal CREB is excluded from the nucleus in response to stress and can be targeted to the mitochondrial to enhance mitochondrial oxidative gene expression11, 12. The report by Chen et al. suggests that CREB nuclear export in a regulatory mechanism that occurs in vivo and correlates with VSMC phenotype. Dynamic CREB nuclear export in the vascular remodeling is similar to other transcriptional responses leading to phenotypic modulation. For example, leupaxin is a LIM protein family member and cofactor for Serum Response Factor (SRF). In response to FAK signaling (such a can be stimulated by fibronectin) leupaxin is sequestered in the cytosol leading to decreased expression of the SRF dependent contractile proteins α-smooth muscle actin and smooth muscle-myosin heavy chain 13. Myocardin and myocardin family members are critical SRF cofactors and determinants of VSMC differentiation. Myocardin is constitutively located in the nucleus, but other family members are translocated to the nucleus in response to activation of Rho kinase on Bone Morphogenic Protein 4 signaling leading to increased VSMC contractile protein expression 14, 15. Thus control of VSMC phenotype is tightly and rapidly regulated by nuclear trafficking.
The new data presented by Chen et al. adds support to the following model: In response to vascular injury VSMC undergo a rapid and reversible phenotype switch to permit wound healing. Nuclear exclusion of CREB and other cofactors is likely a permissive transcriptional modulator of this phenotype switch. Agents or local factors that stimulate nuclear CREB or myocardin nuclear localization, such as nitric oxide or cilostazol, will attenuate the proliferative response at the completion of adaptive remodeling. In disease states with diminished VSMC CREB content, the remodeling response may go unabated thereby contributing to the progression of vascular disease.
Acknowledgments
The author is supported by VA Merit Review (JEBR); UL1 RR025780(JEBR), 1PO1HL014985(JEBR), DK 57516(JEBR), DK064741(JEBR)
1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993 Apr 29;362:801–809. [PubMed]
2. Levin YD, White RJ. Novel therapeutic approaches in pulmonary arterial hypertension: focus on tadalafil. Drugs Today (Barc) Feb;47(2):145–156. [PubMed]
3. Hewer RC, Sala-Newby GB, Wu YJ, Newby AC, Bond M. PKA and Epac synergistically inhibit smooth muscle cell proliferation. Journal of molecular and cellular cardiology. 2011 Jan;50:87–98. [PMC free article] [PubMed]
4. Roscioni SS, Dekkers BG, Prins AG, Menzen MH, Meurs H, Schmidt M, Maarsingh H. cAMP inhibits modulation of airway smooth muscle phenotype via the exchange protein activated by cAMP (Epac) and protein kinase A. British journal of pharmacology. 2011 Jan;162:193–209. [PubMed]
5. Garat CV, Fankell D, Erickson PF, Reusch JE, Bauer NN, McMurtry IF, Klemm DJ. Platelet-derived growth factor BB induces nuclear export and proteasomal degradation of CREB via phosphatidylinositol 3-kinase/Akt signaling in pulmonary artery smooth muscle cells. Mol Cell Biol. 2006 Jul;26:4934–4948. [PMC free article] [PubMed]
6. Klemm DJ, Watson PA, Frid MG, Dempsey EC, Schaack J, Colton LA, Nesterova A, Stenmark KR, Reusch JE. cAMP response element-binding protein content is a molecular determinant of smooth muscle cell proliferation and migration. The Journal of biological chemistry. 2001 Dec 7;276:46132–46141. [PubMed]
7. Tokunou T, Shibata R, Kai H, Ichiki T, Morisaki T, Fukuyama K, Ono H, Iino N, Masuda S, Shimokawa H, Egashira K, Imaizumi T, Takeshita A. Apoptosis induced by inhibition of cyclic AMP response element-binding protein in vascular smooth muscle cells. Circulation. 2003 Sep 9;108:1246–1252. [PubMed]
8. Jambal P, Masterson S, Nesterova A, Bouchard R, Bergman B, Hutton JC, Boxer LM, Reusch JE, Pugazhenthi S. Cytokine-mediated down-regulation of the transcription factor cAMP-response element-binding protein in pancreatic beta-cells. The Journal of biological chemistry. 2003 Jun 20;278:23055–23065. [PubMed]
9. Schauer IE, Knaub LA, Lloyd M, Watson PA, Gliwa C, Lewis KE, Chait A, Klemm DJ, Gunter JM, Bouchard R, McDonald TO, O’Brien KD, Reusch JE. CREB downregulation in vascular disease: a common response to cardiovascular risk. Arteriosclerosis, thrombosis, and vascular biology. 2010 Apr;30:733–741. [PMC free article] [PubMed]
10. Cha-Molstad H, Keller DM, Yochum GS, Impey S, Goodman RH. Cell-type-specific binding of the transcription factor CREB to the cAMP-response element. Proceedings of the National Academy of Sciences of the United States of America. 2004 Sep 14;101:13572–13577. [PubMed]
11. De Rasmo D, Signorile A, Roca E, Papa S. cAMP response element-binding protein (CREB) is imported into mitochondria and promotes protein synthesis. The FEBS journal. 2009 Aug;276:4325–4333. [PubMed]
12. Lee J, Kim CH, Simon DK, Aminova LR, Andreyev AY, Kushnareva YE, Murphy AN, Lonze BE, Kim KS, Ginty DD, Ferrante RJ, Ryu H, Ratan RR. Mitochondrial cyclic AMP response element-binding protein (CREB) mediates mitochondrial gene expression and neuronal survival. The Journal of biological chemistry. 2005 Dec 9;280:40398–40401. [PMC free article] [PubMed]
13. Sundberg-Smith LJ, DiMichele LA, Sayers RL, Mack CP, Taylor JM. The LIM protein leupaxin is enriched in smooth muscle and functions as an serum response factor cofactor to induce smooth muscle cell gene transcription. Circ Res. 2008 Jun 20;102:1502–1511. [PMC free article] [PubMed]
14. Nakamura S, Hayashi K, Iwasaki K, Fujioka T, Egusa H, Yatani H, Sobue K. Nuclear import mechanism for myocardin family members and their correlation with vascular smooth muscle cell phenotype. The Journal of biological chemistry. Nov 26;285:37314–37323. [PubMed]
15. Lagna G, Ku MM, Nguyen PH, Neuman NA, Davis BN, Hata A. Control of phenotypic plasticity of smooth muscle cells by bone morphogenetic protein signaling through the myocardin-related transcription factors. The Journal of biological chemistry. 2007 Dec 21;282:37244–37255. [PMC free article] [PubMed]